Vivet Therapeutics is a biotechnology company developing novel AAV-based gene therapies for rare inherited metabolic diseases. Vivet’s lead product, VTX-801 for the treatment of Wilson’s Disease (WD), is an AAV containing a gene coding for a functional mini-ATP7B copper transporter, that is intended to restore copper metabolism through liver cell targeting.
We have 4 additional gene therapy products under pre-clinical development for rare inherited metabolic liver disorders, including Citrullinemia and PFICs. We also developed a unique technologies platform addressing key challenges of gene therapy, including sustained therapeutic gene expression in young patients and immune responses towards the viral vector.
Vivet Therapeutics is committed to make a significant difference for patients facing rare metabolic diseases. Vivet has a strategic collaboration with Fundación para la Investigación Médica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, University of Navarra, Spain), a leading research organization in the field of Gene Therapy.
Vivet is a 2017’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.